Correlation between mRNAseq expression and clinical features
Liver Hepatocellular Carcinoma (Primary solid tumor)
23 May 2013  |  analyses__2013_05_23
Maintainer Information
Citation Information
Maintained by Juok Cho (Broad Institute)
Cite as Broad Institute TCGA Genome Data Analysis Center (2013): Correlation between mRNAseq expression and clinical features. Broad Institute of MIT and Harvard. doi:10.7908/C1CJ8BJB
Overview
Introduction

This pipeline uses various statistical tests to identify mRNAs whose expression levels correlated to selected clinical features.

Summary

Testing the association between 17848 genes and 7 clinical features across 60 samples, statistically thresholded by Q value < 0.05, 4 clinical features related to at least one genes.

  • 8 genes correlated to 'GENDER'.

    • XIST|7503 ,  TSIX|9383 ,  ZFY|7544 ,  KDM5C|8242 ,  EIF1AX|1964 ,  ...

  • 6 genes correlated to 'LYMPH.NODE.METASTASIS'.

    • DTX3L|151636 ,  CCDC111|201973 ,  CASP3|836 ,  MID2|11043 ,  ACY3|91703 ,  ...

  • 1 gene correlated to 'COMPLETENESS.OF.RESECTION'.

    • SLC16A11|162515

  • 5 genes correlated to 'NEOPLASM.DISEASESTAGE'.

    • CCDC111|201973 ,  SGEF|26084 ,  CASP3|836 ,  DTX3L|151636 ,  ACY3|91703

  • No genes correlated to 'Time to Death', 'AGE', and 'DISTANT.METASTASIS'.

Results
Overview of the results

Complete statistical result table is provided in Supplement Table 1

Table 1.  Get Full Table This table shows the clinical features, statistical methods used, and the number of genes that are significantly associated with each clinical feature at Q value < 0.05.

Clinical feature Statistical test Significant genes Associated with                 Associated with
Time to Death Cox regression test   N=0        
AGE Spearman correlation test   N=0        
GENDER t test N=8 male N=4 female N=4
DISTANT METASTASIS ANOVA test   N=0        
LYMPH NODE METASTASIS ANOVA test N=6        
COMPLETENESS OF RESECTION ANOVA test N=1        
NEOPLASM DISEASESTAGE ANOVA test N=5        
Clinical variable #1: 'Time to Death'

No gene related to 'Time to Death'.

Table S1.  Basic characteristics of clinical feature: 'Time to Death'

Time to Death Duration (Months) 0.1-83.6 (median=14.3)
  censored N = 32
  death N = 23
     
  Significant markers N = 0
Clinical variable #2: 'AGE'

No gene related to 'AGE'.

Table S2.  Basic characteristics of clinical feature: 'AGE'

AGE Mean (SD) 59.66 (15)
  Significant markers N = 0
Clinical variable #3: 'GENDER'

8 genes related to 'GENDER'.

Table S3.  Basic characteristics of clinical feature: 'GENDER'

GENDER Labels N
  FEMALE 23
  MALE 37
     
  Significant markers N = 8
  Higher in MALE 4
  Higher in FEMALE 4
List of 8 genes differentially expressed by 'GENDER'

Table S4.  Get Full Table List of 8 genes differentially expressed by 'GENDER'

T(pos if higher in 'MALE') ttestP Q AUC
XIST|7503 -14.22 1.96e-15 3.5e-11 0.9861
TSIX|9383 -9.48 5.074e-10 9.05e-06 0.9814
ZFY|7544 12.05 2.187e-08 0.00039 0.9919
KDM5C|8242 -6.19 6.706e-08 0.0012 0.8719
EIF1AX|1964 -6.31 7.425e-08 0.00132 0.8754
NLGN4Y|22829 9.56 1.155e-07 0.00206 0.9811
PRKY|5616 9.24 6.111e-07 0.0109 0.9842
TERF1|7013 5.46 1.228e-06 0.0219 0.8496

Figure S1.  Get High-res Image As an example, this figure shows the association of XIST|7503 to 'GENDER'. P value = 1.96e-15 with T-test analysis.

Clinical variable #4: 'DISTANT.METASTASIS'

No gene related to 'DISTANT.METASTASIS'.

Table S5.  Basic characteristics of clinical feature: 'DISTANT.METASTASIS'

DISTANT.METASTASIS Labels N
  M0 39
  M1 1
  MX 20
     
  Significant markers N = 0
Clinical variable #5: 'LYMPH.NODE.METASTASIS'

6 genes related to 'LYMPH.NODE.METASTASIS'.

Table S6.  Basic characteristics of clinical feature: 'LYMPH.NODE.METASTASIS'

LYMPH.NODE.METASTASIS Labels N
  N0 40
  N1 1
  NX 18
     
  Significant markers N = 6
List of 6 genes differentially expressed by 'LYMPH.NODE.METASTASIS'

Table S7.  Get Full Table List of 6 genes differentially expressed by 'LYMPH.NODE.METASTASIS'

ANOVA_P Q
DTX3L|151636 7.274e-10 1.3e-05
CCDC111|201973 8.218e-10 1.47e-05
CASP3|836 4.664e-09 8.32e-05
MID2|11043 4.705e-07 0.0084
ACY3|91703 1.268e-06 0.0226
PARP14|54625 1.724e-06 0.0308

Figure S2.  Get High-res Image As an example, this figure shows the association of DTX3L|151636 to 'LYMPH.NODE.METASTASIS'. P value = 7.27e-10 with ANOVA analysis.

Clinical variable #6: 'COMPLETENESS.OF.RESECTION'

One gene related to 'COMPLETENESS.OF.RESECTION'.

Table S8.  Basic characteristics of clinical feature: 'COMPLETENESS.OF.RESECTION'

COMPLETENESS.OF.RESECTION Labels N
  R0 43
  R1 7
  R2 1
  RX 6
     
  Significant markers N = 1
List of one gene differentially expressed by 'COMPLETENESS.OF.RESECTION'

Table S9.  Get Full Table List of one gene differentially expressed by 'COMPLETENESS.OF.RESECTION'

ANOVA_P Q
SLC16A11|162515 5.168e-08 0.000922

Figure S3.  Get High-res Image As an example, this figure shows the association of SLC16A11|162515 to 'COMPLETENESS.OF.RESECTION'. P value = 5.17e-08 with ANOVA analysis.

Clinical variable #7: 'NEOPLASM.DISEASESTAGE'

5 genes related to 'NEOPLASM.DISEASESTAGE'.

Table S10.  Basic characteristics of clinical feature: 'NEOPLASM.DISEASESTAGE'

NEOPLASM.DISEASESTAGE Labels N
  STAGE I 23
  STAGE II 11
  STAGE IIIA 13
  STAGE IIIB 3
  STAGE IIIC 1
  STAGE IVB 1
     
  Significant markers N = 5
List of 5 genes differentially expressed by 'NEOPLASM.DISEASESTAGE'

Table S11.  Get Full Table List of 5 genes differentially expressed by 'NEOPLASM.DISEASESTAGE'

ANOVA_P Q
CCDC111|201973 1.841e-08 0.000329
SGEF|26084 2.555e-08 0.000456
CASP3|836 7.189e-08 0.00128
DTX3L|151636 7.863e-08 0.0014
ACY3|91703 1.423e-07 0.00254

Figure S4.  Get High-res Image As an example, this figure shows the association of CCDC111|201973 to 'NEOPLASM.DISEASESTAGE'. P value = 1.84e-08 with ANOVA analysis.

Methods & Data
Input
  • Expresson data file = LIHC-TP.uncv2.mRNAseq_RSEM_normalized_log2.txt

  • Clinical data file = LIHC-TP.clin.merged.picked.txt

  • Number of patients = 60

  • Number of genes = 17848

  • Number of clinical features = 7

Survival analysis

For survival clinical features, Wald's test in univariate Cox regression analysis with proportional hazards model (Andersen and Gill 1982) was used to estimate the P values using the 'coxph' function in R. Kaplan-Meier survival curves were plot using the four quartile subgroups of patients based on expression levels

Correlation analysis

For continuous numerical clinical features, Spearman's rank correlation coefficients (Spearman 1904) and two-tailed P values were estimated using 'cor.test' function in R

Student's t-test analysis

For two-class clinical features, two-tailed Student's t test with unequal variance (Lehmann and Romano 2005) was applied to compare the log2-expression levels between the two clinical classes using 't.test' function in R

ANOVA analysis

For multi-class clinical features (ordinal or nominal), one-way analysis of variance (Howell 2002) was applied to compare the log2-expression levels between different clinical classes using 'anova' function in R

Q value calculation

For multiple hypothesis correction, Q value is the False Discovery Rate (FDR) analogue of the P value (Benjamini and Hochberg 1995), defined as the minimum FDR at which the test may be called significant. We used the 'Benjamini and Hochberg' method of 'p.adjust' function in R to convert P values into Q values.

Download Results

This is an experimental feature. The full results of the analysis summarized in this report can be downloaded from the TCGA Data Coordination Center.

References
[1] Andersen and Gill, Cox's regression model for counting processes, a large sample study, Annals of Statistics 10(4):1100-1120 (1982)
[2] Spearman, C, The proof and measurement of association between two things, Amer. J. Psychol 15:72-101 (1904)
[3] Lehmann and Romano, Testing Statistical Hypotheses (3E ed.), New York: Springer. ISBN 0387988645 (2005)
[4] Howell, D, Statistical Methods for Psychology. (5th ed.), Duxbury Press:324-5 (2002)
[5] Benjamini and Hochberg, Controlling the false discovery rate: a practical and powerful approach to multiple testing, Journal of the Royal Statistical Society Series B 59:289-300 (1995)